<DOC>
	<DOCNO>NCT01887314</DOCNO>
	<brief_summary>The purpose study verify capability standardize Ginger ( Zingiber officinale ) extract manage nausea cancer patient receive highly emetogenic treatment standard anti-emetogenic therapy .</brief_summary>
	<brief_title>Efficacy Study Ginger ( Zingiber Officinale ) Extract `` Ginpax '' Manage Nausea Cancer Patients Receiving High Emetogenic Treatments Standard Anti-emetogenic Therapy</brief_title>
	<detailed_description>This study randomize , double-blind , placebo control , multicenter study two parallel group patient . The study conduct 5 Italian clinical site involve 250 patient receive least 2 cycle highly emetogenic treatment . Patients randomly assign Ginger treatment Placebo . All patient receive , chemotherapy cycle , standard 5-HT3 receptor antagonist antiemetic plus dexamethasone NK1 receptor antagonist . This guarantee patient antiemetic prophylaxis acute delay nausea . No additional treatment usually foreseen nausea justifies use placebo control group . Patients start study treatment day chemotherapy cycle continue day follow cycle ; suspend study treatment chemotherapy day start next day . The choice treat patient study product chemotherapy day intend avoid possible interference antiemetic therapy first day chemotherapy , analyze impact Ginger delay phase without confound factor acute phase . Main efficacy assessment study : - To evaluate protection delay nausea ( incidence delay nausea non-significant delayed nausea ) ; Other efficacy assessment regard nausea evaluate : - To evaluate severity delay nausea ; - To evaluate overall duration nausea ; - To evaluate inter cycle nausea ; - To evaluate nausea anticipatory symptom 2nd cycle . Secondary efficacy assessment study : - To evaluate protection delay vomiting ( number emetic episode delayed phase ) ; - To evaluate impact nausea/vomiting daily life activity ( FLIE30 questionnaire ) ; - To evaluate use antiemetic rescue medication ; - To evaluate compliance treatment ; - To assess overall fatigue ( BFI31 questionnaire ) . Safety assessment study : - Number typology adverse event .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Male Females age &gt; 18 year . Na√Øve chemotherapy . Patients plan receive least 2 cycle highly emetogenic treatment cisplatin single dose &gt; 50 mg/m2 every 21 28 day . Willing able understand sign inform consent complete patient diary . Presence brain symptomatic metastasis ( case small , asymptomatic metastasis absence steroid treatment , patient eligible ) . Scheduled receive receive past 4 week radiation treatment brain , abdomen pelvis . Emesis significant nausea within 24 hour first chemotherapy cycle . Known hypersensitivity reaction Ginger component product . Patients coagulopathies cause potential increase risk bleed . Patients therapy oral anticoagulant . Planned surgery procedure period study within 2 week study conclusion . History seizure . Active use cannabinoids . Known current past drug alcohol abuse . Use investigational drug within 30 day study entry study . Clinically significant finding physical exam presence know clinically significant disease would interfere study evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Nausea</keyword>
	<keyword>Ginger</keyword>
	<keyword>Zingiber officinale</keyword>
	<keyword>5HT3</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Neurokinin-1 ( NK-1 )</keyword>
	<keyword>Interleukin-6 ( IL-6 )</keyword>
	<keyword>Tumor necrosis factor-alpha ( TNF-alpha )</keyword>
	<keyword>Insulin like growth factor-1 ( IGF-1 )</keyword>
	<keyword>Placebo</keyword>
	<keyword>FLIE</keyword>
	<keyword>BFI</keyword>
</DOC>